RAF antisense oligonucleotide as a tumor radiosensitizer.
about
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateAvoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)Ultrasmall glutathione-protected gold nanoclusters as next generation radiotherapy sensitizers with high tumor uptake and high renal clearance.Gene therapy strategies to improve the effectiveness of cancer radiotherapy.Raf kinases: function, regulation and role in human cancer.Dosimetry and risk from low- versus high-LET radiation of Auger events and the role of nuclide carriers.Selective Raf inhibition in cancer therapy.Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.Update on novel agents in renal cell carcinoma.Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.Hepatitis B virus regulation of Raf1 promoter activity through activation of transcription factor AP-2α.Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling.Signaling perturbations induced by invading H. pylori proteins in the host epithelial cells: a mathematical modeling approach.Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant gliomaSmall interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo.Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway.Sorafenib and thyroid cancer
P2860
Q24619987-E6873F4D-092B-4955-BA5F-720E25375FAEQ28079359-72BAF4B3-693A-4B14-A38F-1656DB1F5406Q35133948-3448DA1B-2736-4650-B04D-C6BA07D1350BQ35925611-A5A189AE-A732-4B5F-ACE4-7283F51C6766Q36002845-70255A9A-9FA6-4618-93CA-52C2087FF952Q36069684-55FDAB68-40E8-4C98-9E32-BFEAD43ED7B4Q37004743-84874C2F-0A28-477F-9080-B9B5ACE09B23Q37321859-0CBF1B73-CC90-41F0-A219-0616F57AE7BBQ37399265-B2F29E6E-B7FE-49DA-9977-8F5BEF7599D6Q37642798-5D7E8E10-A128-41AB-B852-9104D3118D10Q39203692-056B7991-B1E2-4A57-B101-64A9FA7E2D27Q39229719-FFD88EE8-172C-44EA-AAA6-5A40FCC94AE5Q40035207-2B18240E-4794-4818-A583-CA3C3E267825Q40199892-B63B11F3-4994-4BDD-BB3E-79513731F136Q40368977-766BDAB2-6336-440D-93A6-8F120598F734Q41346638-62709931-A65B-4ACD-B232-293CD825DF03Q46415504-B9D42EEB-7653-45F1-93BB-DDDB8EDAEC18Q49335746-DB35D613-99C2-4092-BEEA-45E9B522C0A8Q56504638-D68D9827-A587-494B-B3E8-A562B9B41621
P2860
RAF antisense oligonucleotide as a tumor radiosensitizer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
RAF antisense oligonucleotide as a tumor radiosensitizer.
@ast
RAF antisense oligonucleotide as a tumor radiosensitizer.
@en
type
label
RAF antisense oligonucleotide as a tumor radiosensitizer.
@ast
RAF antisense oligonucleotide as a tumor radiosensitizer.
@en
prefLabel
RAF antisense oligonucleotide as a tumor radiosensitizer.
@ast
RAF antisense oligonucleotide as a tumor radiosensitizer.
@en
P2860
P356
P1433
P1476
RAF antisense oligonucleotide as a tumor radiosensitizer.
@en
P2093
Anatoly Dritschilo
Usha Kasid
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206700
P407
P577
2003-09-01T00:00:00Z
P5875
P6179
1016329018